Hepatic injury and pancreatitis during treatment with serotonin reuptake inhibitors: Data from the World Health Organization (WHO) database of adverse drug reactions

International Clinical Psychopharmacology

Volumn 18, Issue 3, 2003, Pages 157-161

  Spigset, Olav ^a   Hägg, Staffan ^b,c   Bate, Andrew ^b,d  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d UPPSALA MONITORING CENTRE   (Sweden)

Author keywords

Adverse drug reaction reporting systems; Adverse effect; Hepatic failure; Hepatitis; Hepatotoxicity; Nefazodone; Pancreatitis; Selectiv e serotonin reuptake inhibitors; Venlafaxine

Indexed keywords

CITALOPRAM; FLUOXETINE; FLUVOXAMINE; NEFAZODONE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ACUTE PANCREATITIS; ARTICLE; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; HEPATITIS; HUMAN; LIVER FAILURE; LIVER INJURY; LIVER NECROSIS; LIVER TOXICITY; PANCREATITIS; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RISK FACTOR; WORLD HEALTH ORGANIZATION;

ADVERSE DRUG REACTION REPORTING SYSTEMS; BAYES THEOREM; CYCLOHEXANOLS; DATABASES, FACTUAL; HUMANS; LIVER DISEASES; NEURAL NETWORKS (COMPUTER); PANCREATITIS; SEROTONIN UPTAKE INHIBITORS; TRIAZOLES; WORLD HEALTH ORGANIZATION;

EID: 0038740699     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200305000-00006     Document Type: Article

References (41)

1. Anonymous (2002). Physicians' Desk Reference, 56th edn. Montvale: Medical Economics Company.
2. Aranda-Michel J, Koehler A, Bejarno PA, Poulos JE, Luxon BA, Khan CM, et al. (1999), Nefazodone-induced liver failure: report of three cases. Ann Intern Med 130:285-288.
3. Azaz-Lisvits T, Hershko A, Ben-Chetrir E (2002). Paroxetine associated hepatotoxicity: a report of 3 cases and a review of the literature. Pharmacopsychiatry 35:112-115.
4. Bamrah JS, Benbow SM, McKenna J (1990). Fluvoxamine and liver enzymes. Br J Psychiatry 156:286-287.
5. Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, et al. (1998). A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 54:315-21.
6. Benbow SJ, Gill G (1997). Paroxetine and hepatotoxicity. BMJ 314:1387.
7. Blomgren KB, Sundström A, Steineck G, Genell S, Sjöstedt S, Wiholm B-E (2002). A Swedish case-control network for studies of drug-induced morbidity-acute pancreatitis. Eur J Clin Pharmacol 58:275-283.
8. Bobichon R, Bernard G, Mion F (1993). Acute hepatitis during treatment with fluoxetine. Gastroenterol Clin Biol 17:406-407.
9. Cadranel JF, Di Martino V, Cazier A, Pras A, Bachmeyer C, Olympi P, et al. (1999). Atrium and paroxetine-related severe hepatitis. J Clin Gastroenterol 28:52-55.
10. Cai Q, Benson MA, Talbot TJ, Devadas G, Swanson HJ, Olson JL, et al. (1999). Acute hepatitis due to fluoxetine therapy. Mayo Clin Proc 74;692-694.
11. Capellà D, Bruguera M, Figueras A, Laporte J-R (1999). Fluoxetine-induced hepatitis: why is postmarketing surveillance needed? Eur J Clin Pharmacol 55;545-546.
12. Cardona X, Avila A, Castellanos P (2000), Venlafaxine-associated hepatitis. Ann Intern Med 132:417.
13. Castiella A, Arenas JI (1994). Fluoxetine hepatotoxicity. Am J Gastroenterol 89:458-459.
14. Collet JP, Boivin JF, Spitzer WO (1994.) Bias and confounding in pharmacoepidemiology. In: Strom BL (editor): Pharmacoepidemiology, 2nd edn. Chichester: John Wiley & Sons; pp, 609-627.
15. de Man RA (1997). Severe hepatitis attributes to paroxetine (Seroxat). Ned Tijdschr Geneeskd 141:540-542.
16. Edwards IR, Wiholm B-E, Martinez C (1996). Concepts in risk-benefit assessment. Drug Safety 15:1-7.
17. Eloubeidi MA, Gaede JT, Swaim MW (2000). Reversible nefazodone-induced liver failure. Dig Dis Sci 45:1036-1038.
18. Fartoux-Heymann L, Hezode C, Zafrani ES, Dhumeaux D, Mallat A (2001). Acute fatal hepatitis related to sertraline. J Hepatol 35:683-684.
19. Food and Drug Administration (2002). Important drug warning including black box information. http://www.fda.gov/medwatch/SAFETY/2002/serzone_-deardoc.pdf.
20. Friedenberg FK, Rothstein KD (1996). Hepatitis secondary to fluoxetine treatment. Am J Psychiatry 153:580.
21. Garcia-Pando AC, de IPozo JG, Sánchez AS, Martín V, de Castro AMR, Lucena MI (2002), Hepatotoxicity associated with the new antidepressants. J Clin Psychiatry 63:135-137.
22. Green BH (1998). Fluvoxamine and hepatic function. Br J Psychiatry 153:130-131.
23. Hautekeete ML, Colle I, van Vlierberghe H, Elewaut A (1998). Symptomatic I iver injury probably related to sertraline. Gastroenterol Clin Biol 22:364-365.
24. Helmchen C, Boerner RJ, Meyendorf R, Hegerl U (1996). Reversible hepatotoxicity of paroxetine in a patient with major depression. Pharmacopsychiatry 29;223-226.
25. Horsmans Y, de Clerq M, Sempoux C (1999). Venlafaxine-associated hepatitis. Ann Intern Med 130:944.
26. Johnston DE, Wheeler DE (1997). Chronic hepatitis related to use of fluoxetine, Am J Gastroenterol 92:1225-1226.
27. Kim KY, Hwang W, Narendran R (1999). Acute liver damage possibly related to sertraline and venlafaxine. Ann Pharmacother 33:381-382.
28. Kvande KT, Madsen S (2000). Selective serotonin uptake inhibitors and pancreatitis. Tidsskr Nor Laegeforen 121:177-178.
29. Lam KS, Blanchi A, Chavaillon JM (1988). Hepatitis probably secondary to the massive ingestion of fluvoxamine. Gastroenterol Clin Biol 12:398-399.
30. Lindquist M, Edwards IR, Bate A, Fucik H, Nunes AM, Ståhl M (1999). From association to alert - a revised approach to international signal analysis. Pharmacoepidemiol Drug Safety 8 (suppl 1 ):15-25.
31. Lindquist M, Ståhl M, Bate A, Edwards IR, Meyboom RHB (2000). A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database. Drug Safety 23:533-542.
32. Lucena MI, Andrade RJ, Gomez-Outes A, Rubio M, Cabello MR (1999). Acute liver failure after treatment with nefazodone. Dig Dis Sci 44:2577-2579.
33. Mars F, Dumas de la Roque G, Goissen P (1991). Acute hepatitis during treatment with fluoxetine. Gastroenterol Clin Biol 15:270-271.
34. Mortimer Ö, Yue Q-Y (2000). Nefadar (nefazodon) kan ge allvarliga leverbiverkningar. Information from the Swedish Med Prod Agency 11:43-44.
35. Odeh M, Misselevech I, Boss JH, Oliven A (2001). Severe hepatotoxicity with jaundice associated with paroxetine. Am J Gastroenterol 96;2494-2496.
36. Orre R, Lansner A, Bate A, Lindquist M (2000). Bayesian neural networks with confidence estimations applied to data mining. Comput Stat Data Analysis 34:473-493.
37. Schirren CA, Baretton G (2000). Nefazodone-induced acute liver failure. Am J Gastroenterol 95:1596-1597.
38. Schrader GD, Roberts-Thompson IC (1999). Adverse effect of nefazodone-hepatitis. Med J Aust 170:452.
39. ten Ham M (1992). WHO's role in international ADR monitoring. Post Mark Surveillance 5:223-230.
40. van Battum PLH, van de Vrie W, Metselaar HJ, Verstappen VMC, Zondervan PE, de Man RA (2000), Acuut leverfalen toegeschreven aan nefazodon. Ned Tijdschr Geneeskd 144:1964-1967.
41. Verrico MM, Nace DA, Towers AL (2000). Fulminant chemical hepatitis possibly associated with donepezil and sertraline therapy. J Am Geriatr Soc 48:1659-1663.